Autoimmune hepatitis is an independent risk factor for allograft loss and morbidity after liver transplantation: evidence from the Swiss Transplant Cohort Study

BACKGROUND: Liver transplantation is the only curative option for end-stage autoimmune hepatitis (AIH). Although overall outcomes are favourable, previous studies suggest an increased risk of allograft loss and mortality in this population. We assessed post-liver transplantation outcomes in AIH recipients using data from the nationwide multicentre Swiss Transplant Cohort Study (STCS). METHODS: We included all adult patients undergoing a first liver transplantation between May 2008 and December 2020. Indications were categorised as AIH, alcohol-related liver disease, viral liver disease, primary biliary cholangitis, primary sclerosing cholangitis, metabolic dysfunction-associated liver disease or other/mixed aetiologies. Survival analyses and multivariable competing risk Cox models were applied. Clinical Registration number (CER-VD): 2021-01982. RESULTS: Among 880 liver transplantation recipients, 23 (2.6%) underwent liver transplantation for AIH. The 1-, 5- and 10-year post-liver transplantation survival rates in the AIH group were 87.0%, 76.5% and 76.5%, respectively – comparable to other indications. Allograft failure occurred in 34.8% of AIH recipients, significantly more often than in alcohol-related liver disease (8.3%, p <0.001), viral liver disease (13.5%, p = 0.003), primary sclerosing cholangitis (12.2%, p = 0.029) and metabolic dysfunction-associated liver disease (8.2%, p = 0.005). On multivariable analysis, AIH remained independently associated with increased allograft loss (HR 4.23, 95% CI 1.85–9.64; p = 0.003). Hepatic artery thrombosis occurred in 4/23 AIH patients and caused early allograft failure in all cases. CONCLUSION: Despite comparable long-term survival, AIH recipients had a higher risk of early allograft loss, with vascular complications contributing to several early failures. Although the small AIH sample limited the precision of the estimated effects, these findings suggest the need for tailored pre- and post-transplant surveillance with particular attention to vascular complications.

Authors

Institutions

Publication Details

Journal
Swiss Medical Weekly
Published
2026-11-16
DOI
https://doi.org/10.57187/5375
Primary Topic
Liver Diseases and Immunity
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Autoimmune hepatitis is an independent risk factor for allograft loss and morbidity after liver transplantation: evidence from the Swiss Transplant Cohort Study

Julien Vionnet, Linard Hoessly, Markus Hermann Heim, G. Magini et al.
1 links
Swiss Medical Weekly
Liver Diseases and Immunity
article

Autoimmune hepatitis is an independent risk factor for allograft loss and morbidity after liver transplantation: evidence from the Swiss Transplant Cohort Study

Julien Vionnet, Linard Hoessly, Markus Hermann Heim, G. Magini, M. Pascual, Beat Müllhaupt, José Oberholzer, Nasser Semmo, Mirjam Kolev, Susanne Stampf, Darius Moradpour, Nicolas Goossens, David Semela, the Swiss Transplant Cohort Study, Aurélie Rosat, Montserrat Fraga, Andreas Kremer, Vanessa Banz, Benedetta Terziroli Beretta-Piccoli, Philippe Compagnon, Simon Brunner, Annalisa Berzigotti, Michael Koller
article en

Abstract

BACKGROUND: Liver transplantation is the only curative option for end-stage autoimmune hepatitis (AIH). Although overall outcomes are favourable, previous studies suggest an increased risk of allograft loss and mortality in this population. We assessed post-liver transplantation outcomes in AIH recipients using data from the nationwide multicentre Swiss Transplant Cohort Study (STCS). METHODS: We included all adult patients undergoing a first liver transplantation between May 2008 and December 2020. Indications were categorised as AIH, alcohol-related liver disease, viral liver disease, primary biliary cholangitis, primary sclerosing cholangitis, metabolic dysfunction-associated liver disease or other/mixed aetiologies. Survival analyses and multivariable competing risk Cox models were applied. Clinical Registration number (CER-VD): 2021-01982. RESULTS: Among 880 liver transplantation recipients, 23 (2.6%) underwent liver transplantation for AIH. The 1-, 5- and 10-year post-liver transplantation survival rates in the AIH group were 87.0%, 76.5% and 76.5%, respectively – comparable to other indications. Allograft failure occurred in 34.8% of AIH recipients, significantly more often than in alcohol-related liver disease (8.3%, p <0.001), viral liver disease (13.5%, p = 0.003), primary sclerosing cholangitis (12.2%, p = 0.029) and metabolic dysfunction-associated liver disease (8.2%, p = 0.005). On multivariable analysis, AIH remained independently associated with increased allograft loss (HR 4.23, 95% CI 1.85–9.64; p = 0.003). Hepatic artery thrombosis occurred in 4/23 AIH patients and caused early allograft failure in all cases. CONCLUSION: Despite comparable long-term survival, AIH recipients had a higher risk of early allograft loss, with vascular complications contributing to several early failures. Although the small AIH sample limited the precision of the estimated effects, these findings suggest the need for tailored pre- and post-transplant surveillance with particular attention to vascular complications.

Swiss Medical WeeklyVol. 156(11)
University of Bern (CH), University of Basel (CH), University of Zurich (CH), Kantonsspital St. Gallen (CH), University Hospital of Bern (CH), Centre Hospitalier Universitaire Vaudois (CH), University Hospital of Basel (CH), Ente Ospedaliero Cantonale (CH), University Hospital of Zurich (CH), University Hospital of Geneva (CH), Kantonsspital Graubünden (CH), Università della Svizzera italiana (CH), University of Lausanne (CH)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Université de Lausanne, Swiss Transplant Cohort Study
Good health and well-being
Liver Diseases and Immunity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon